TITakuya Izumi-Tamura

Takuya Izumi-Tamura

*This is an algorithmically generated author record based on publicly available information.

Takuya Izumi-Tamura has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Multiplex Immunofluorescence–Defined CXCL13-Associated TLS-like Niches Predict Outcomes in Bladder Cancer

    by Ryoichi Maenosono, Kazuki Nishimura, Takuya Tsujino, Yuki Yoshikawa, Kensuke Hirosuna, Moritoshi Sakamoto, Tomohisa Matsunaga, Maiko Seki, Asuka Kawachi, Takuya Izumi-Tamura, et al.

    Purpose: Spatially organized tertiary lymphoid structure (TLS)–like niches may provide prognostic and therapeutic information beyond individual immune mediators such as CXCL13 in bladder cancer. We evaluated the clinical and translational significance of multiplex immunofluorescence (mIF)–defined TLS-like structures (mTLS) in bladder cancer. Experimental Design: We analyzed 469 clinically annotated bladder cancer tumors using 41-plex mIF with the PhenoCycler platform. Bulk RNA sequencing, CIBERSORTx deconvolution, Cox modeling with CXCL13 as a continuous variable, and spatial neighborhood analysis were used to define mTLS-associated immune programs. Orthotopic bladder cancer mouse models treated with cisplatin and/or recombinant Cxcl13 followed by anti–PD-L1 blockade were analyzed by flow cytometry. Results: mTLS were identified in 22.2% of tumors and were not apparent on routine histopathology. mTLS positivity was associated with immune activation, improved survival, and favorable response patterns in a small PD-L1 blockade–treated subset. In Cox models, mTLS remained independently associated with outcomes, whereas continuous CXCL13 expression was not significant. Spatial profiling showed CXCL13/CXCR5-enriched B- and T-cell neighborhoods, including CXCL13-expressing and CXCR5-positive CD8+ T-cell subsets. In mouse models, cisplatin plus exogenous Cxcl13 was associated with lymphocyte infiltration, enrichment of CD8+ PD-1+ and CD8+ Cxcr5+ Cxcl13+ T-cell states, and sustained tumor control after PD-L1 blockade. Conclusions: mIF-defined mTLS identify a clinically relevant spatial immune architecture linked to favorable outcomes and therapeutic responsiveness in bladder cancer. These findings support prospective evaluation of mTLS as a spatial biomarker for risk stratification and treatment sequencing, with CXCL13/CXCR5 features interpreted as contextual companion markers rather than standalone determinants.


  • Open Access

    The Impact of Splicing Factor Mutations on Clonal Hematopoiesis and Myeloid Neoplasm Progression

    by Takuya Izumi-Tamura, Asuka Kawachi, Akihide Yoshimi

    Clonal hematopoiesis (CH) is characterized by the expansion of hematopoietic stem and progenitor cells harboring somatic mutations, which confers an increased risk of hematologic malignancies and cardiovascular disease. Among CH-associated mutations, mutations affecting splicing factors (SFs), including splicing factor 3b subunit 1 (SF3B1), serine/arginine-rich splicing factor 2 (SRSF2), U2 small nuclear RNA auxiliary factor 1 (U2AF1), and zinc finger CCCH-type, RNA binding motif and serine/arginine rich 2 (ZRSR2), play a unique role in promoting clonal expansion and leukemogenesis. In this review, we summarize recent findings on the role of SF mutations in CH progression, their interplay with other mutations (e.g., DNA methyltransferase 3 alpha (DNMT3A), ten-eleven translocation methylcytosine dioxygenase 2 (TET2) and isocitrate dehydrogenase 2 (IDH2)), and their impact on hematopoietic homeostasis. Epidemiological studies have demonstrated that SF-mutant CH exhibits an accelerated clonal expansion compared to other CH clones. Furthermore, murine models suggest that SF mutations alone do not inherently confer a growth advantage for clonal expansion but rather enhance disease phenotypes when co-existing with epigenetic mutations, such as IDH2 and TET2. These findings suggest that SF mutations contribute to CH expansion and malignant transformation through a synergistic interplay with other mutations and external factors such as inflammation. Given the clinical significance of SF mutations, ongoing research is focused on developing targeted therapies that modulate aberrant RNA splicing and prevent CH-driven leukemogenesis. Understanding the mechanisms underlying mutant spliceosome-mediated CH expansion may provide novel insights into early detection, risk stratification, and therapeutic interventions in hematologic malignancies.


  • Increased SLAMF7high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab

    by Takaaki Maekawa, Shoichiro Kato, Toshikuni Kawamura, Kohei Takada, Takehiro Sone, Hiraku Ogata, Keita Saito, Takuya Izumi, Shigeki Nagao, Kosuke Takano, et al.

    Monocyte-derived fibrocytes recently garnered attention as the novel pathogenesis of myelofibrosis (MF) and suppression of fibrocyte differentiation by serum amyloid P remarkably improved MF. We previously revealed that human fibrocytes highly expressed signaling lymphocytic activation molecule-F7 (SLAMF7) compared with macrophages and that SLAMF7high monocytes in the peripheral blood (PB) of MF patients were significantly elevated relative to healthy controls (HCs). In this study, we evaluated SLAMF7high monocyte percentage in PB of HCs, myeloproliferative neoplasm (MPN) patients without MF, and MPN patients with MF using a cross-sectional approach. We found that MPN patients harboring JAK2V617F with MF had a significantly elevated SLAMF7high monocyte percentage, which correlated positively with the JAK2V617F allele burden. Additionally, the serum concentration of IL-1ra was significantly correlated with the SLAMF7high monocyte percentage and JAK2V617F allele burden. These findings suggest that both SLAMF7high monocytes and IL-1ra could be a useful non-invasive marker of MF onset. Furthermore, the JAK2V617F allele burden of SLAMF7high monocytes was significantly higher than that of SLAMF7low monocytes and could be a potential target of elotuzumab (Elo), an anti-SLAMF7 antibody used for treating multiple myeloma. Elo independently inhibited differentiation of fibrocytes not only derived from HCs but also derived from MF patients in vitro. Elo also ameliorated MF and splenomegaly induced by romiplostim administration in humanized NOG mice. In conclusion, an increase of SLAMF7high monocytes with higher JAK2V617F allele burden was associated with the MF onset in MPN patients harboring JAK2V617F, and Elo could be a therapeutic agent for MPN patients harboring JAK2V617F with MF. Key Points SLAMF7high CD16negative monocytes increased in peripheral blood of patients with myelofibrosis in correlation with JAK2V617F mutation. Anti-SLAMF7 antibody suppressed monocyte-derived fibrocyte differentiation and could be a potent therapeutic agent for myelofibrosis.